{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:06:14Z","timestamp":1789571174845,"version":"build-2803163510"},"reference-count":27,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030841","name":"Exact Sciences Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100030841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Breast cancer is the most common cancer among women in the USA, accounting for approximately 31% of new cases and 15% of cancer-related deaths in females. Triple-negative breast cancer (TNBC) is the most lethal subtype with 29 months median overall survival. Despite curative-intent surgery and systemic adjuvant therapy, many patients remain at risk for recurrence. We developed a comprehensive model for patients with operable stage II and III TNBC, adhering to the current standard-of-care clinical follow-up recommendations, to evaluate the effectiveness of these recommendations in detecting recurrence among patients with newly diagnosed TNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>An individual-level state transition (microsimulation) model was built with a lifetime horizon using monthly cycles. The model integrated treatment and surveillance recommendations per current guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The currently recommended treatment and surveillance modalities by the National Comprehensive Cancer Network guidelines for surveilling patients with TNBC after diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Female patients aged 49 years who were newly diagnosed with operable stage II or III TNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Cumulative recurrences, detected recurrences, detection rate, overall survival and recurrence-free survival in a 5-year horizon, as well as average life expectancy, were the outcome measures used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our model estimated a 5-year overall survival rate of 81.4%\u00b10.1% (SE) for patients with stage II or III TNBC, with a recurrence-free survival rate of 78.3%\u00b10.1% (SE). Over the same period, 7.4%\u00b10.1% (SE) of patients with TNBC were projected to experience recurrences (68% distant recurrence, 32% locoregional recurrence), with a detection rate of only 59.3%\u00b10.2% (SE) among these recurrences. Our model estimated that 399 mammograms would be required to detect one locoregional recurrence and 279 other imaging tests would be needed to identify one distant recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our clinically validated model sheds light on the outcomes for patients with TNBC, revealing the limitations in recurrence detection rates associated with current guidelines. These findings underscore the need for improved strategies during the surveillance period. As novel testing methods become available, this model can be instrumental in exploring how these innovations may improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-115240","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:55:23Z","timestamp":1789570523000},"page":"e115240","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrence detection in patients with triple-negative breast cancer following the current standard of care: a microsimulation model"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3980-8188","authenticated-orcid":false,"given":"Sumeyye","family":"Samur","sequence":"first","affiliation":[{"name":"Value Analytics Labs, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oya","family":"Hoban","sequence":"additional","affiliation":[{"name":"Value Analytics Labs, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning Yan","family":"Gu","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebra Cuyun","family":"Carter","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Palomares","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Arrick","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Gursel","sequence":"additional","affiliation":[{"name":"Value Analytics Labs, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Value Analytics Labs, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8720-0280","authenticated-orcid":false,"given":"Turgay","family":"Ayer","sequence":"additional","affiliation":[{"name":"H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology College of Engineering, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-4430","authenticated-orcid":false,"given":"Jagpreet","family":"Chhatwal","sequence":"additional","affiliation":[{"name":"Institute for Technology Assesment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A","family":"Parsons","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutch Cancer Center; and Hematology & Oncology, University of Washington, Seattle, Washington, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026091607550928000_16.9.e115240.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"2026091607550928000_16.9.e115240.2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27581"},{"key":"2026091607550928000_16.9.e115240.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"2026091607550928000_16.9.e115240.4","doi-asserted-by":"crossref","DOI":"10.3892\/mco.2022.2528","article-title":"Racial disparities in health insurance, triple-negative breast cancer diagnosis, tumor stage, treatment and survival in a large nationwide SEER cohort in the United States","volume":"16","author":"Du","year":"2022","journal-title":"Mol Clin Oncol"},{"key":"2026091607550928000_16.9.e115240.5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512478","article-title":"Advances in the Management of Early-Stage Triple-Negative Breast Cancer","volume":"24","author":"Bhardwaj","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026091607550928000_16.9.e115240.6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31914"},{"key":"2026091607550928000_16.9.e115240.7","unstructured":"National Comprehensive Cancer Network . Breast cancer (version 4.2022)."},{"key":"2026091607550928000_16.9.e115240.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651"},{"key":"2026091607550928000_16.9.e115240.9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30689-8"},{"key":"2026091607550928000_16.9.e115240.10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jss.2019.09.072","article-title":"Validation of the Prognostic Significance of the Prognostic Stage Group According to the Eighth Edition of American Cancer Joint Committee on Cancer Staging System in Triple-Negative Breast Cancer: An Analysis From Surveillance, Epidemiology, and End Results 18 Database","volume":"247","author":"Luo","year":"2020","journal-title":"J Surg Res"},{"key":"2026091607550928000_16.9.e115240.11","first-page":"1","article-title":"United States Life Tables, 2020","volume":"71","author":"Arias","year":"2022","journal-title":"Natl Vital Stat Rep"},{"key":"2026091607550928000_16.9.e115240.12","unstructured":"Triple-negative breast cancer survival and recurrence rates. Available: https:\/\/www.medicalnewstoday.com\/articles\/324272#treatment [Accessed May 2025]."},{"key":"2026091607550928000_16.9.e115240.13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2217\/fon-2020-1021","article-title":"Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer","volume":"17","author":"Skinner","year":"2021","journal-title":"Future Oncol"},{"key":"2026091607550928000_16.9.e115240.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"2026091607550928000_16.9.e115240.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07508-2"},{"key":"2026091607550928000_16.9.e115240.16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2021.39.15_suppl.543","article-title":"Survival following locoregional recurrence in breast cancer by clinical subtype","volume":"39","author":"Allen","year":"2021","journal-title":"JCO"},{"key":"2026091607550928000_16.9.e115240.17","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/djac131","article-title":"Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)","volume":"114","author":"Schumacher","year":"2022","journal-title":"JNCI"},{"key":"2026091607550928000_16.9.e115240.18","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454579"},{"key":"2026091607550928000_16.9.e115240.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6494-3","article-title":"AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer","volume":"20","author":"He","year":"2020","journal-title":"BMC Cancer"},{"key":"2026091607550928000_16.9.e115240.20","unstructured":"U.S. Food and Drug Administration . 2021. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer"},{"key":"2026091607550928000_16.9.e115240.21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s12325-022-02365-1","article-title":"Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States","volume":"40","author":"Huang","year":"2023","journal-title":"Adv Ther"},{"key":"2026091607550928000_16.9.e115240.22","unstructured":"Triple negative breast cancer. Available: https:\/\/www.nationalbreastcancer.org\/triple-negative-breast-cancer [Accessed Apr 2025]."},{"key":"2026091607550928000_16.9.e115240.23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10549-016-3757-4","article-title":"Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study","volume":"156","author":"van Roozendaal","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2026091607550928000_16.9.e115240.24","doi-asserted-by":"crossref","first-page":"v","DOI":"10.3310\/hta15340","article-title":"The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation","volume":"15","author":"Robertson","year":"2011","journal-title":"Health Technol Assess"},{"key":"2026091607550928000_16.9.e115240.25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40273-021-01121-7","article-title":"Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review","volume":"40","author":"Huang","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"2026091607550928000_16.9.e115240.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2021.04.330","article-title":"PCN240 Healthcare Resource Utilization Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer","volume":"24","author":"Sieluk","year":"2021","journal-title":"Value in Health"},{"key":"2026091607550928000_16.9.e115240.27","doi-asserted-by":"publisher","DOI":"10.4174\/astr.2023.104.1.1"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-115240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:55:27Z","timestamp":1789570527000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-115240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,16]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2025-115240"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-115240","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}